Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Ibuprofen for Prevention of Post-ERCP Pancreatitis
NCT02241512Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibuprofen in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), sponsored by UT Southwestern Medical Center. Started Sep 2014; status: terminated.
02
Drugs
ibuprofen
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT02241512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241512.